Shire Sells Dermagraft To Organogenesis At $650M Loss
Irish biopharmaceuticals company Shire PLC announced Friday that it has sold its skin substitute product Dermagraft to U.S.-based Organogenesis Inc. in a deal that pays Shire nothing upfront and leaves it...To view the full article, register now.
Already a subscriber? Click here to view full article